EGFR and cancer: Although these precision therapies could work well in most cancers with general targets, its feasibility in mutated cancer types such as non-small-cell lung cancer of adenocarcinoma with EGFR mutation (~29.3% of all) or triple-negative breast cancer (11.2% of all) is strongly restricted by the availability of small molecular or monoclonal antibody (Midha et al., 2015 #190, Tan and Dent, 2018 #191).